GeneDx Holdings (WGS) Cost of Revenue (2020 - 2026)

GeneDx Holdings has disclosed Cost of Revenue across 7 years of filings, most recently posting $34.0 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 18.87% year-over-year to $34.0 million; the TTM figure through Mar 2026 stood at $134.8 million (up 9.03% YoY), while the FY2025 annual figure was $129.4 million, up 16.49% from the prior year.
• Cost of Revenue slipped to $34.0 million in Q1 2026, from $36.7 million in the prior quarter.
• Over the last five years, Cost of Revenue for WGS reached as high as $77.7 million in Q4 2022 and fell as low as $15.2 million in Q2 2023.
• The 5-year median for Cost of Revenue is $28.6 million (2025), against an average of $31.8 million.
• Annual changes were most pronounced in 2023 — Cost of Revenue tumbled 79.97% — and 2024, when it soared 294.36%.
• A 5-year view of Cost of Revenue shows it stood at $77.7 million in 2022, then plunged by 79.97% to $15.6 million in 2023, then soared by 294.36% to $61.4 million in 2024, then slumped by 40.15% to $36.7 million in 2025, then slipped by 7.29% to $34.0 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $34.0 million, $36.7 million, and $32.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.